Recent Updates
Recently added Catalysts
ATYR Negative Sentiment Score: 20/100

aTyr Pharma, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before December 8, 2025 to Discuss Your Rights – ATYR

Key Takeaway: aTyr Pharma, Inc. is involved in a class action securities lawsuit filed by Levi & Korsinsky, LLP, which seeks to recover losses for investors affected by alleged securities fraud between November 2024 and September 2025. The lawsuit highlights false statements made by the company regarding the efficacy of their drug Efzofitimod, particularly related to tapering steroid use. The issue escalated after the EFZO-FIT study did not meet its primary endpoint, causing the company’s stock to drop sharply from $6.03 to $1.02 over a two-day period. Investors have until December 8, 2025, to join the lawsuit and potentially seek compensation.

Market Sentiment Analysis

CONCERNS & RISKS

  • aTyr Pharma is facing a class action lawsuit for alleged securities fraud.
  • The company did not meet the primary endpoint in their Efzofitimod study, leading to significant investor loss.
  • Following disappointing study results, aTyr's stock price plummeted 83.2% in one day.

Full Press Release Details

NEW YORK, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of aTyr investors who were adversely affected by alleged securities fraud between November 7, 2024 and September 12, 2025. Follow the link below to get more information and be contacted by a member of our team:
ATYR investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy of Efzofitimod, particularly, the drug’s capability to allow a patient to completely taper their steroid usage. The truth emerged on September 15, 2025 (pre-market) when aTyr hosted an investor call announcing that the EFZO-FIT study did not meet its primary endpoint. In pertinent part, defendants announced that the study did not meet the primary endpoint in change from baseline in mean daily OSC dose at week 48. Additionally, aTyr announced that the Company’s next step was to engage with the FDA to determine a path forward, given the disappointing topline results. Following this news, the price of aTyr’s common stock declined from a closing market price of $6.03 per share on September 12, 2025 to $1.02 per share on September 15, 2025, a decline of 83.2% in the span of just a single day.
WHAT'S NEXT? If you suffered a loss in aTyr during the relevant time frame, you have until December 8, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the aTyr Pharma class action lawsuit about?

The lawsuit addresses alleged securities fraud affecting aTyr investors from Nov 7, 2024, to Sep 12, 2025.

How did aTyr's stock price change after the EFZO-FIT study results?

Following the study's disappointing results, aTyr's stock fell from $6.03 to $1.02, an 83.2% drop.

What is the deadline to become a lead plaintiff in this lawsuit?

Potential lead plaintiffs must file by December 8, 2025.

Is there any cost to join the aTyr Pharma class action?

Participation in the class action involves no out-of-pocket costs for members.

Why choose Levi & Korsinsky for this case?

Levi & Korsinsky has a strong track record, securing millions for investors over 20 years.

Last updated: Nov 11, 2025